F Fuzkk Atlas of the USA
#285Extended selection 101–500

Remix Therapeutics

Massachusetts / New England

RNA and genetic medicines

Manufacturing profile

RNA and genetic medicines

Biopharma hub: Massachusetts / New England

Selection basis

The company is placed in positions 101–500 as a manufacturer, biotech, generics, advanced-therapy company or CDMO with practical relevance to the FUZKK utility catalog.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Representative manufacturing and QC chain

  1. 1Template, oligonucleotide or vector starting materials
  2. 2Synthesis, transcription or delivery-particle preparation
  3. 3Purification and sequence/identity confirmation
  4. 4Potency, integrity, impurities and particle analytics
  5. 5Sterile filling, stability and cold-chain evidence

Relevant FUZKK packages

United States: national essential medicines QC packageChina: national essential medicines QC packageLumex QC SuiteLabEx QC SuiteMedical Device QMS Suite

Product/API utilities

Assay & Impurities Result Reviewer

Lumex — instrumental QC

Genotoxic Impurity Screener M7Content Uniformity Acceptance ValueSystem Suitability Parameters Checker

LabEx — laboratory QC

Assay & Impurity HPLC Quality CheckerResidual Solvents GC Quality CheckerWater Content KF Quality Checker

Medical Devices — equipment and software lifecycle

Release Readiness CheckerSupplier Evaluation CheckerCalibration Status CheckerProcess Validation CheckerChange Control Impact CheckerData Integrity Security CheckerRequirement Traceability Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Methodology